Examining the efficacy of the short MDR-TB regimen: alternative analyses from the STREAM trial

Patrick Phillips, Saiam Ahmed, Sarah Meredith, I.D. Rusen, Andrew Nunn, and the STREAM collaboration
STREAM Randomized Controlled Trial (Nunn et al., NEJM, 2019)

• Main (efficacy) finding:
  • The **Short 9-11 month injectable-containing regimen** was non-inferior to the **Long 20+ month WHO regimen** with respect to the primary efficacy outcome.

• HIV-adjusted difference between regimens
  • Modified ITT: 1.0% (95% CI -7.5%, 9.5%)
  • Per protocol: -0.7% (95% CI -10.5%, 9.1%)

• “There were, however, **some differences in the components of the composite outcome that merited further investigation**…
  • **bacteriologic unfavourable outcomes** were more common in the **Short regimen**, 
  • whereas **loss to follow-up** was more common in the **Long regimen**.”
WHO end of treatment outcomes for RR-TB

WHO outcomes for RR-TB with relapse added

TB-NET MDR-TB outcomes (Lange, NEJM, 2016)

Modified MDR-TB outcomes for short regimens (Schwoebel, IJTL, 2019)

End of follow-up outcomes, ignoring treatment changes

Approach 1.
Time to a Failure or Relapse (FoR) event

Re-classification of all ‘unfavourable’ and ‘not assessable’ events:
What was the likelihood that it was a pre-cursor of a FoR event?

Each box represents the outcome for a single study participant

Consider Highly Likely and Probable as events;
Possible, Unlikely, Highly Unlikely censored.

At risk
Short 253 240 223 208 205 203 197
Long 130 124 119 112 107 104 101

- Short, 25 (9.9%) events
- Long, 6 (4.6%) events
Sensitivity analyses to account for non-independent censoring

1. Inverse probability of censoring weighting (IPCW)
   • Up-weighting of comparable non-censored patients in the analysis
   • **Probability of censoring model** includes:
     • Baseline factors:
     • Cumulative number of grade 3-5 AEs experienced

2. Multiple imputation with imposed departures from independent censoring
   • **Imputation model** includes:
     • Baseline factors,
     • Likelihood of Failure or Relapse (FoR),
     • and user-specified (log) ratio of hazard of FoR event between censored and non-censored individuals (γ)

<table>
<thead>
<tr>
<th></th>
<th>Hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unadjusted, assuming independent censoring</td>
<td>2.19 (0.90, 5.35)</td>
</tr>
<tr>
<td>Adjusted, assuming independent censoring</td>
<td>2.08 (0.85, 5.07)</td>
</tr>
<tr>
<td>Adjusted, using IPCW for non-independent censoring</td>
<td>2.08 (0.83, 5.20)</td>
</tr>
</tbody>
</table>
Conclusions

1. Alternative efficacy outcomes are for programmatic reporting and are not well suited to clinical trials,
   • But nonetheless gave between-regimen results that were consistent with the primary analysis of the composite outcome.

2. From post hoc analyses, the hazard of failure or relapse is likely to be higher in the Short 9-11 month regimen than in the Long regimen,
   • Results depend how Possible and Unlikely events are considered in the analysis.

3. We believe time to failure or relapse event is an improvement on a composite outcome and should be considered as a primary outcome for future treatment trials in DS- and DR-TB.
Acknowledgements

Patients and their families who participated in the STREAM trial, and all STREAM partners.

This study is made possible by the generous support of the American people through the United States Agency for International Development (USAID) through the TREAT TB Cooperative Agreement No. GHN-A-00-08-00004. The contents are the responsibility of the authors and do not necessarily reflect the views of USAID or the United States Government.